GlaxoSmithKline (GSK) and Theravance, Inc. THRX today announced that the licence application for the use of fluticasone furoate (FF) and vilanterol (VI) (proposed brand name RELVAR™ ELLIPTA™) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results